Bio Essence Corporation carries a market capitalization of 10.69M, placing it among publicly traded companies globally. Its enterprise value stands at 6.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.69M |
| Enterprise Value | 6.96M |
Bio Essence Corporation currently has 46.81M shares outstanding.
| Shares Outstanding | 46.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Bio Essence Corporation trades at a trailing price-to-earnings ratio of 4.15. The price-to-sales ratio is 2.28, and the price-to-book ratio stands at -0.58.
| PE Ratio | 4.15 |
| PS Ratio | 2.28 |
| PB Ratio | -0.58 |
| P/TBV Ratio | -3.80 |
| P/FCF Ratio | 4.58 |
| P/OCF Ratio | 4.58 |
On an enterprise value basis, Bio Essence Corporation trades at an EV/EBITDA multiple of 5.27 and an EV/FCF ratio of 5.87. The EV/Sales ratio of 2.93 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.27 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.93 |
| EV / EBITDA | 5.27 |
| EV / EBIT | 5.27 |
| EV / FCF | 5.87 |
Bio Essence Corporation maintains a current ratio of 0.37, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -109.70, indicating conservative leverage, while an interest coverage ratio of 604.64 demonstrates strong ability to service its debt obligations.
| Current Ratio | 0.37 |
| Quick Ratio | 0.25 |
| Debt / Equity | -109.70 |
| Debt / EBITDA | 1.19 |
| Interest Coverage | 604.64 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 226.43 |
| Return on Invested Capital (ROIC) | -929.52 |
| Return on Capital Employed (ROCE) | -16.70 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Over the trailing twelve months, Bio Essence Corporation has paid 10,639.00 in income taxes, reflecting an effective tax rate of 0.81.
| Income Tax | 10,639.00 |
| Effective Tax Rate | 0.81 |
Bio Essence Corporation's stock has gained approximately 145.45455% over the past 52 weeks. The 50-day moving average sits at 0.29, while the 200-day moving average is 0.17.
| Beta (5Y) | N/A |
| 52-Week Price Change | 145.45455% |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | 0.17 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Bio Essence Corporation generated 2.38M in revenue and converted that into 1.31M in net income, yielding earnings per share of 0.03. EBITDA reached 1.32M, while operating income came in at 1.32M.
| Revenue | 2.38M |
| Gross Profit | 1.73M |
| Operating Income | 1.32M |
| Pretax Income | 1.32M |
| Net Income | 1.31M |
| EBITDA | 1.32M |
| EBIT | 1.32M |
| Earnings Per Share (EPS) | 0.03 |
Bio Essence Corporation holds 36,177.00 in cash and equivalents against 1.57M in total debt, resulting in a net debt position of 20,983.00. Total book value stands at -9.34M, with working capital of -1.37M providing operational flexibility.
| Cash & Cash Equivalents | 36,177.00 |
| Total Debt | 1.57M |
| Net Debt | 20,983.00 |
| Equity (Book Value) | -9.34M |
| Book Value Per Share | -0.23 |
| Working Capital | -1.37M |
Bio Essence Corporation produced 1.18M in operating cash flow over the past twelve months.
| Operating Cash Flow | 1.18M |
| Capital Expenditures | N/A |
| Free Cash Flow | 1.18M |
| FCF Per Share | 0.03 |
Bio Essence Corporation operates with a gross margin of 72.70, reflecting its pricing power and cost economics. The operating margin of 55.60 and net profit margin of 55.02 provide insight into operational efficiency.
| Gross Margin | 72.70 |
| Operating Margin | 55.60 |
| Pretax Margin | 55.47 |
| Profit Margin | 55.02 |
| EBITDA Margin | 55.61 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 21.15 |
| FCF Yield | 21.81 |
Bio Essence Corporation posts an Altman Z-Score of -8.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -8.67 |